TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21808760
Drug: Brånemark (Nobel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brånemark (Nobel Biocare) implants
Study: 20874829
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant systems
Study: 11934971
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (GTN) 2% ointment applied for 1 minute
Study: 11934971
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied for 1 minute
Study: 11934971
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated finger)
Study: 9469350
Drug: I.V.‐oral regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V.‐oral regimen
Study: 7612061
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 150 mg ranitidine + 4 x 500 mg amoxicillin for 2 weeks, followed by 300 mg ranitidine for 2 weeks
Study: 7612061
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 300 mg ranitidine + 4 x 500 mg amoxicillin for 2 weeks, followed by 300 mg ranitidine for 2 weeks
Study: 2242456
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg daily (increased to a maximum of 200 micrograms daily)
Study: 38176
Drug: None of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: None of the drugs
Study: 23872125
Drug: C500 (C0+500
Approvals — FDA: no, EMA: no, PMDA: no
Description: C500 (C0+500 g/t aflatoxin biodegradation preparations)
Study: 23872125
Drug: C1000 (C0+1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1000 (C0+1000 g/t aflatoxin biodegradation preparations)
Study: 23872125
Drug: M500 (M0+500
Approvals — FDA: no, EMA: no, PMDA: no
Description: M500 (M0+500 g/t aflatoxin biodegradation preparations)
Study: 23872125
Drug: M1000 (M0+1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: M1000 (M0+1000 g/t aflatoxin biodegradation preparations)
Study: 23872125
Drug: M2000 (M0+2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2000 (M0+2000 g/t aflatoxin biodegradation preparations)
Study: 21674848
Drug: gabapentin-NSAID-morphine
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gabapentin-NSAID-morphine
Study: 11041313
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 and 10 mg/70 kg)
Study: 9347207
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug (NSAID) after the first dose of misoprostol
Study: 9347207
Drug: No nonsteroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nonsteroidal anti-inflammatory drug after the first dose of misoprostol
Study: 9347207
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug after the second dose of misoprostol
Study: 9347207
Drug: No nonsteroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nonsteroidal anti-inflammatory drug after the second dose of misoprostol
Study: 8111210
Drug: Foot reflexotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot reflexotherapy (FR) plus conventional Western medicine (hypoglycemic agent)
Study: 3089360
Drug: Salt added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt added to lentils (4.25 g)
Study: 3089360
Drug: Salt added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt added to bread (4.25 g)
Study: 17576868
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg
Study: 22362559
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin 1 mg/kg followed by TNK-tPA
Study: 22362559
Drug: Supplemental IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental IV enoxaparin 0.3 mg/kg
Study: 22362559
Drug: IV enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV enoxaparin 0.3 mg/kg
Study: 18561117
Drug: Ciclesonide 200
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 200 microg once daily
Study: 10903487
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 microg twice daily
Study: 16350719
Drug: Methylprednisolone i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone i.v. pulses followed by oral prednisone treatment (Group I)
Study: 16350719
Drug: Anti-thyroid drugs
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thyroid drugs (Group II)
Study: 7878754
Drug: CsA-ME (microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA-ME (microemulsion formulation)
Study: 7878754
Drug: CsA-GC (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA-GC (corn oil-based soft gel cap)
Study: 2228838
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g iv
Study: 31502749
Drug: dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dapagliflozin 10 mg
Study: 20333744
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional laser treatment
Study: 17092377
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg)
Study: 1944909
Drug: Felbamate (2,300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbamate (2,300 mg/d)
Study: 31583708
Drug: Smartphone-based exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based exposure treatment
Study: 11943440
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment A
Study: 20551460
Drug: Mesalazine 4
Normalized name: Mesalazine 400 mg gastro-resistant and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 4 g/day
Study: 7722711
Drug: Atole (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atole (high energy and high protein supplement: 163 kcals/682 kJ and 11.5 g protein per cup or 180 mL)
Study: 7722711
Drug: Fresco (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresco (low energy, no protein supplement: 59 kcals/247 kJ in 180 mL)
Study: 7722711
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (immigrants, n = 144)
Study: 1723468
Drug: Nitrendipine once
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine once daily
Study: 1723468
Drug: Nitrendipine twice
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine twice daily
Study: 11044759
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other pharmacological agents)
Study: 8513519
Drug: Intramuscular Meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Meperidine (IM)
Study: 2950914
Drug: Topical ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketoconazole shampoo
Study: 28968858
Drug: 33% tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33% tapering TNFi
Study: 28968858
Drug: 66% tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: 66% tapering TNFi
Study: 26659791
Drug: sifalimumab (200-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sifalimumab (200-1200 mg) administered intravenously every 4 weeks for 52 weeks
Study: 26659791
Drug: fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed dosing of sifalimumab
Study: 19571155
Drug: Cinnamon extract
Normalized name: Cinnamon Extract
DrugBank: Chinese cinnamon (DB16593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon extract (Cinnulin PF) 250 mg, two times per day for 12 weeks
Study: 15059043
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 40 mg once daily for 4 weeks
Study: 15059043
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 40 mg once daily for 10 days
Study: 15059043
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 40 mg once daily for 5 days
Study: 15059043
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 40 mg (single-dose study)
Study: 15059043
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole (first week) followed by oral esomeprazole
Study: 7530677
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally twice a day until ANC was 1,000/microliters (Group I, n=29)
Study: 7530677
Drug: G‐CSF from
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF from Day 2 until ANC was greater than 10,000/microliters (Group II, n=15)
Study: 7530677
Drug: Ciprofloxacin with
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin with G‐CSF prophylaxis (n=24)
Study: 3652622
Drug: Intravenous frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide (30 mg)
Study: 25197804
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (100 mg)
Study: 3652622
Drug: Oral carbidopa
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral carbidopa (100 mg)
Study: 27279471
Drug: High-dose RO
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose RO extract (HRE) 1800 mg/day
Study: 27279471
Drug: Low-dose RO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose RO extract (LRE) 900 mg/day
Study: 28828394
Drug: Teriflunomide 14
Normalized name: teriflunomide 14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide 14 mg
Study: 22622860
Drug: Teriflunomide 7
Normalized name: teriflunomide 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide 7 mg
Study: 23733165
Drug: Monopolar spray
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monopolar spray coagulation (Group A)
Study: 20419973
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of verapamil every 14 days for 6 months
Study: 16882525
Drug: Water treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water treatment (active)
Study: 11076816
Drug: Continuous prostacyclin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous prostacyclin infusion
Study: 3901764
Drug: Prepidil gel
Normalized name: dinoprostone Vaginal Gel [Prepidil]
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prepidil gel (0.5 mg)
Study: 26423685
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after Axitinib
Study: 15584064
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine 20 mg twice daily
Study: 15584064
Drug: Topical 0.2
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2 percent glyceryl trinitrate ointment
Study: 11903078
Drug: Epidural PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural PCA with bupivacaine 0.06% and sufentanil 1 microg x ml(‐1)
Study: 11903078
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.15 mg
Study: 9619712
Drug: Goserelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin plus mitomycin (14 mg/m2 i.v. every 6 weeks)
Study: 2939217
Drug: Ketanserin monotherapy
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin monotherapy
Study: 901134
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy intervention
Study: 901134
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy intervention (second year participants)
Study: 31658111
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality intervention in addition to Traditional Occupational Therapy
Study: 31658111
Drug: Traditional Occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Occupational Therapy
Study: 19400831
Drug: 0.1% copper-zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% copper-zinc malonate-containing cream applied twice daily
Study: 14750756
Drug: 0.3 mg/mL
Normalized name: menthol 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/mL of adjunctive mitomycin C for 3 minutes
Study: 10693993
Drug: Amoxicillin/clavulanate (45/6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days)
Study: 10693993
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg on Day 1, then 5 mg/kg daily on Days 2 through 5)
Study: 9114916
Drug: GR 32191
Normalized name: cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GR 32191 (20 mg and 40 mg, orally)
Study: 3080882
Drug: Prazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (1 to 8 mg per day)
Study: 3080882
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 240 mg per day)
Study: 3351815
Drug: Danazol treatment
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol treatment (6-month course)
Study: 30731474
Drug: Linaclotide (290
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide (290 μg)
Study: 3839796
Drug: Prostaglandin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin inhibitor (naproxen sodium)
Study: 24461665
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (PN)
Study: 24461665
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (PN)
Study: 23592317
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1,000 mg) and Vitamin E (400 IU)
Study: 22909282
Drug: P. ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. ginseng extract (1 g/day)
Study: 22909282
Drug: P. ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. ginseng extract (2 g/day)
Study: 12492745
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg
Study: 19076084
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of indapamide retard with or without addition of 2‐4 mg of perindopril
Study: 9513587
Drug: Nebulized furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized furosemide (40 mg)
Study: 6109234
Drug: Phloctaphenin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloctaphenin (200 mg)
Study: 6109234
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (200 mg)
Study: 29166321
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g low glycemic index modified starch supplement (UCAN)
Study: 29166321
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g high glycemic index glucose‐based supplement (G)
Study: 27421617
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy delivered by telephone (CBT-T)
Study: 27421617
Drug: Telephone-delivered nondirective
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered nondirective supportive therapy (NST-T)
Study: 25386945
Drug: Common Elements
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common Elements Treatment Approach (CETA) delivered by lay counselors
Study: 16899484
Drug: PATHOZYME‐TB Complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATHOZYME‐TB Complex Plus commercial ELISA kit measuring immunoglobulin G against 38‐kDa and 16‐kDa recombinant antigens
Study: 9667276
Drug: Postoperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative therapy
Study: 29976173
Drug: Point-of-care Circulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care Circulating Cathodic Antigen (POC-CCA) test integrated with praziquantel (PZQ) treatment.
Study: 29976173
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) treatment without testing.
Study: 27700210
Drug: Boron-based gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron-based gel
Study: 22788723
Drug: AR-NT (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-NT (no surface treatment)
Study: 21492364
Drug: Rivoglitazone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 0.5 mg daily
Study: 21492364
Drug: Rivoglitazone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 1.0 mg daily
Study: 21492364
Drug: Rivoglitazone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 1.5 mg daily
Study: 24843782
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg daily
Study: 21492364
Drug: Rivoglitazone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone 1.0 mg and 1.5 mg
Study: 15609596
Drug: Self-prepared ear-dropping
Normalized name: Sus scrofa ear preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-prepared ear-dropping made by combined Chinese and Western drugs
Study: 11067720
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Paroxetine
Study: 27595728
Drug: 20% benzocaine
Normalized name: BENZOCAINE 200 mg in 1 g DENTAL GEL [Ipana 20% Benzocaine Topical]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% benzocaine gel
Study: 8638859
Drug: Belief manipulation
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belief manipulation (active agent vs placebo)
Study: 2513966
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam elixir (0.3 mg/kg)
Study: 2513966
Drug: Intramuscular papaveretum
Normalized name: papaveretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular papaveretum with hyoscine (0.3 mg/kg with 0.006 mg/kg)
Study: 166586
Drug: Cytarabine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine (50 mg/m² body surface area, subcutaneously, once daily for 4 days)
Study: 24633388
Drug: Antiplatelet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet and antithrombotic therapy (AP/AT)
Study: 24633388
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet and antithrombotic therapy (AP/AT)
Study: 26554619
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hyoscine‐N‐butylbromide
Study: 12556949
Drug: Actimel (fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actimel (fermented milk preparation)
Study: 12556949
Drug: Indian Dahi
Normalized name: Indian frankincense
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indian Dahi (fermented milk preparation)
Study: 12556949
Drug: Ultra-heat-treated yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-heat-treated yoghurt preparation (control group)
Study: 8733313
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (1000 kcal/day, casein based enteral nutritional formula)
Study: 8733313
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (using pressure threshold load valve at 30% of Maximal Inspiratory Mouth Pressure) with nutritional supplement
Study: 8733313
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (using pressure threshold load valve) without nutritional supplement
Study: 8733313
Drug: No training
Approvals — FDA: no, EMA: no, PMDA: no
Description: No training or nutritional supplement
Study: 2665800
Drug: Betamethasone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (3 injections or more)
Study: 2665800
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 injections or more)
Study: 2665800
Drug: Betamethasone (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (before 34 weeks gestation, 3 injections or more)
Study: 2665800
Drug: Placebo (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (before 34 weeks gestation, 3 injections or more)
Study: 30664539
Drug: Combined Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Cognitive Processing Therapy (CPT) and smoking cessation treatment
Study: 30664539
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment without CPT
Study: 25140039
Drug: Afatinib (A)
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib (A) 40 mg/day
Study: 25140039
Drug: Temozolomide (T)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (T) 75 mg/m2 for 21 of 28 days
Study: 24024757
Drug: Sodium alginate
Normalized name: Sodium Alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium alginate suspension 20 mL three times a day
Study: 7926494
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily
Study: 15328899
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 mg titrated to 5 mg)